Jasper Therapeutics Announces Development Prioritization of Briquilimab In Chronic Diseases

Jasper Therapeutics Inc JSPR will focus on developing its lead product candidate, briquilimab (formerly JSP191), in chronic diseases and stem cell transplants for rare diseases.
This portfolio includes a new program on chronic urticaria, along with the company's existing programs for lower-risk myelodysplastic syndrome (MDS), sickle cell disease, Fanconi anemia, and severe combined immunodeficiency (SCID).
Based on preclinical and clinical studies showing inhibition of c-Kit signaling and depletion of mast cells, Jasper has prioritized starting a clinical study in severe chronic urticaria.
While the company has no near-term plans to initiate a Phase 3 study in AML/MDS, it will continue to work with the FDA to explore development pathways and ensure briquilimab remains ready for a pivotal Phase 3 study in AML/MDS stem cell transplant.
Last week, Jasper Therapeutics announced data from the first three participants in a Phase 1/2 trial of adding briquilimab to an existing bone marrow transplantation regimen in individuals with sickle cell disease and beta-thalassemia.
Price Action: JSPR shares are up 13.20% at $1.80 on the last check Tuesday.